This facility is capable of manufacturing, packaging, testing, storage and distribution of sterile injectables, oral tablets and Capsules, and is supplying to US, Europe and other markets across the globe. The US sales of products manufactured at this plant was less than 1% of the total business of the company for the first half year of FY25-26 and less than 5% of the total business of the company for FY24-25. Source link India Sena-BJP Fissures Open Up In… Avaada to invest Rs 1 lakh cr in 5… Top 5 equity mutual funds deliver… CISF revises posting policy for… Stock…